Composite endpoints in clinical trials

Revista Espanola de Cardiologia

Volumn 61, Issue 3, 2008, Pages 283-290

  Ferreira González, Ignacio ^a,b   Alonso Coello, Pablo ^a,c   Solà, Ivan ^a,c   Pacheco Huergo, Valeria ^a,d   Domingo Salvany, Antònia ^a,e   Alonso, Jordi ^a,e   Montori, Víctor ^a,f   Permanyer Miralda, Gaietà ^a,b  

^a CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Sant Feliu de Llobregat   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f Mayo Clinic   (United States)

Author keywords

Clinical trials; Composite endpoints; Heterogeneity

Indexed keywords

FIBRIC ACID DERIVATIVE; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ROSIGLITAZONE; TENECTEPLASE;

ACUTE HEART INFARCTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EMPIRICISM; HUMAN; MORTALITY; REVIEW; RISK FACTOR; SAMPLE SIZE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CARDIOVASCULAR DISEASE; HEART INFARCTION; OUTCOME ASSESSMENT; STATISTICAL ANALYSIS; STATISTICS;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 44449156429     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13116656     Document Type: Review

References (12)

1. Moyé LA. Multiple analyses in clinical trials. Springer; 2003.
2. Neaton JD, Gray G, Zuckerman BD, Konstam MA. Key issues in end point selection for heart failure trials: composite end points. J Card Fail. 2005;11:567-75.
3. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 2003;289:2554-9.
4. Ferreira-Gonzalez I, Permanyer-Miralda G, Busse JW, Bryant DM, Montori VM, Alonso-Coello P, et al. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J Clin Epidemiol. 2007;60:651-7.
5. Montori VM, Permanyer-Miralda G, Ferreira-Gonzalez I, Busse JW, Pacheco-Huergo V, Bryant D, et al. Validity of composite end points in clinical trials. BMJ. 2005;330:594-6.
6. Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ. 2007;334:786.
7. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003;108:135-42.
8. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-61.
9. del Amo J, Perez-Hoyos S, Moreno A, Quintana M, Ruiz I, Cisneros JM, et al. Trends in AIDS and mortality in HIV-infected subjects with hemophilia from 1985 to 2003: the competing risks for death between AIDS and liver disease. J Acquir Immune Defic Syndr. 2006;41:624-31.
10. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53.
11. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; published online Sept 15. DOI:10.1016/S0140-6736(06)69420-8.
12. Aldamiz-Echevarría B, Muñiz J, Rodríguez- Fernández JA, Vidán-Martínez L, Silva-César M, Lamelo-Alfonsín F, et al. Ensayo clínico aleatorizado y controlado para valorar una intervención por una unidad de hospitalización domiciliaria en la reducción de reingresos y muerte en pacientes dados de alta del hospital tras un ingreso por insuficiencia cardiaca. Rev Esp Cardiol. 2007;60: 914-22.